All News

Lindsay Tom

Hidden in Plain Sight: IBD

Lindsay Tom PA-C

As a PA with six years of experience in rheumatology and a background in gastroenterology, today I'm discussing the clinical overlap between inflammatory arthritis—particularly psoriatic arthritis and spondyloarthropathies—and inflammatory bowel disease.

Read Article
EULAR.Docs.APP

Role of the Nurse in the Care and Management of Rheumatic Diseases - EULAR Review

Jack Cush, MD

In 2023, a EULAR subcommittee set out to assess the roles of nurses and Advanced Practice Nurses (APN) in the care of arthritis as outlined in published EULAR guidelines. The scope of APN practices was first proposed in 2012 and revised in 2018.

Read Article
RheumNow Podcast square

Reefer Madness (12.12.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal and regulatory reports from this past week on RheumNow.com.  B cell drugs in SLE and ITP, biomarkers in GCA & PSS and great videos by APPs.

Read Article
Eval of Rheum Complaints Cover Image

Evaluation of Rheumatic Complaints

Jack Cush, MD

Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.

Read Article
labs.tubes_.jpg

British Society of Rheumatology Guideline for Monitoring DMARDs

Jack Cush, MD

The British Society of Rheumatology has published an update to their previous 2017 BSR/BHPR guideline regarding the use and monitoring of DMARDs (disease-modifying anti-rheumatic drugs) used to treat systemic autoimmune rheumatic diseases (SARDs). 

Read Article
PSA2L.jpg

Consensus Definitions on Difficult to Treat Psoriatic Arthritis

Jack Cush, MD

A substantial number of patients with psoriatic arthritis (PsA), have difficult, persistent and hard-to-treat disease. A GRAPPA task force has developed a consensus terminology for two distinct states: complex-to-manage PsA and treatment-refractory PsA.

Read Article
RheumNow Podcast square

Turkey Tryptophan (11.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?

Read Article
Tarsal Tunnel Syndrome - review and quiz. A compressive neuropathy of the posterior tibial nerve within the tarsal tunnel. 80% caused by lipoma, ganglion, varicosity, trauma, tenosynovitis, rheumatoid arthritis, diabetes, etc https://t.co/zCyeVIJEuy https://t.co/f4jA13FDvN

Links:

Dr. John Cush RheumNow ( View Tweet)
Israeli retrospective study of 9736 colchicine Rx FMF pts matched w/ 97 360 controls. On F/U Psoriatic arthritis developed in more FMF pts (43 vs 119) - HR 3.52 (CI: 2.48, 5.0). ^Risk w/ older age, smoking, SES https://t.co/blDIsmHWPC

Links:

Dr. John Cush RheumNow ( View Tweet)

Cases & Guidelines: Tuesday Night Rheumatology Panelists discuss their approaches to a range of difficult cases in multiple areas, including RA, PsA and PMR. Panelists: Audrey Gibson, PA-C; Benjamin A. Smith, PA-C; Emma Bavage, ANP; Jack Cush, MD https://t.co/1HPBdPdIVx https://t.co/30Q6azQU3r

Links:

Dr. John Cush RheumNow ( View Tweet)
Taiwanese retrospective study (2001-2022) of 2,383 PsA pts Rx w/ 1+ DMARDs. Comparing 1,190 bDMARDs vs 1,193 cDMARD Rx pts, bDMARDs assoc. w/ signif lower risk of MACE (HR 0.65), all-cause mortality (0.44), CV mortality (0.54), but more infx related Hosp (1.45) https://t.co/eu7fSVkjZl
Dr. John Cush RheumNow ( View Tweet)
The countdown is on! ⏱️ Drs. Jack Cush & Artie Kavanaugh are previewing what’s coming to RheumNow Live 2026 in Dallas (Feb 7–8) – and you don’t want FOMO on this one. ✅ Register now at https://t.co/4UQlqwujiR 🔥Early bird pricing ends December 15 – Get the inside scoop on https://t.co/K6kxX2oDtu

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Flare or Beware Lindsay Tom, PA-C and Phong Nguyen, MD, Reston, VA discuss today's case called "Flare or Beware", involving a patient who has psoriatic arthritis mutilans, presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of https://t.co/JbyHBCQ4ct
Dr. John Cush RheumNow ( View Tweet)
Consensus Definitions on Difficult to Treat PsA A substantial number of patients with PsA, have difficult, persistent and hard-to-treat disease. A GRAPPA task force has developed a consensus terminology for two distinct states: Complex-to-manage PsA (C2M-PsA) https://t.co/po1psn9GNm
Dr. John Cush RheumNow ( View Tweet)
Turkey Tryptophan (11.28.2025) Dr. Jack Cush reviews the news and reports from this past week on RheumNow, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders? https://t.co/cnxxwqwyTE https://t.co/82zugQnp2Y

Links:

Dr. John Cush RheumNow ( View Tweet)
CBC & Psoriasis - case–control study 60 pts: 30 PsA & 30 PSO pts showed that PsA showed elevated WBCs, neutrophils, monocytes & inflammatory markers (NLR, MLR, SII, SIRI, & decr PMR (all p < 0.001). NLR 100% Dx accuracy (AUC = 1.000). WBC > 6.7, MLR > 0.17, & PMR ≤ 503 were https://t.co/AB7iFiMuSM
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow (November 2025) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side https://t.co/mX0Hv1RRF9
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2026 is coming February 7th and 8th to Dallas, Texas - and registration is now open! Ready for the most interactive, engaging and practice-changing rheumatology meeting of the year? This year’s program covers vasculitis, autoimmune disease, PsA, RA outcomes, https://t.co/cftvdSn3t7
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2026 is coming February 7th and 8th to Dallas, Texas - and registration is now open! This year’s program covers vasculitis, autoimmune disease, PsA, RA outcomes, spondyloarthritis, and much more. Reserve your spot today at https://t.co/o78Pc8LPsQ https://t.co/GOUW5Od9Hy

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 452 #PsA pts who failed 1st line TNFi Rx (LOE) - 275 Cycled to another TNFi vs 177 Swapped to an IL-17i. Higher Retention in Swap (78%) vs cycled (68%) PsA pts (p < 0.001) @12 mos (60 v 40%@3yrs). Tx failure predicted by cycling, Dz Activity, Rx year, axial & mixed https://t.co/VQLBlBEw4W
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×